By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen said today that it has acquired a minority stake in Alacris Theranostics, a startup using whole-genome sequence analysis to develop individualized cancer therapies.

Qiagen has also acquired a minority stake in EyeSense, a developer of ophthalmic diagnostic systems for glucose monitoring of diabetes patients, EyeSense said in a separate announcement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.